TABLE 1.

Clinical characteristics and outcomes of 294 patients with MSSA-B who were enrolled in the cohort study

CharacteristicVancomycin treatment (n = 27)aBeta-lactam treatment (n = 267)aP value
Age (yr, mean ± SD)52.1 ± 18.456.0 ± 17.40.26
Male gender16 (59)164 (61)0.83
Community-acquired infection12 (44)147 (55)0.29
Length of hospital stay before SAB
    <72 h12 (44)147 (55)0.29
    3-7 days3 (11)32 (12)0.89
    8-28 days8 (30)65 (24)0.47
    >28 days4 (15)23 (9)0.29
McCabe classification
    Nonfatal6 (22)97 (36)0.14
    Ultimately fatal13 (48)120 (45)0.75
    Rapidly fatal8 (30)50 (19)0.18
Underlying diseases
    Solid tumor5 (19)55 (21)0.80
    Hematologic malignancy7 (26)51 (19)0.40
    Liver cirrhosis5 (19)49 (18)0.98
    End stage renal disease3 (11)32 (12)0.89
    Cardiovascular disease7 (26)17 (6)0.003
Primary sites of infection
    Unknown10 (37)84 (32)0.55
    Catheter-related infectionb3 (11)62 (23)0.15
    Pneumonia3 (11)25 (9)0.77
    Soft tissue infection2 (7)42 (16)0.40
    Surgical wound infection2 (7)10 (4)0.30
Eradicated foci of infection8 (30)94 (35)0.56
Neutropenia8 (30)40 (15)0.06
Infection acquired in intensive care unit5 (19)17 (6)0.04
Previous admission history10 (37)86 (32)0.61
Previous antibiotic use15 (56)71 (27)0.002
Previous surgery3 (11)23 (9)0.72
Defervescence (days, mean ± SD)5.0 ± 6.23.5 ± 2.80.08
Duration of treatmentc (days, mean ± SD)20.2 ± 12.421.9 ± 13.90.63
Combination treatment0 (0)11 (4)0.61
Metastatic infection8 (30)50 (18)0.18
Infective endocarditis4 (15)9 (3)0.02
Overall deaths11 (41)65 (24)0.06
30-day deaths9 (33)49 (18)0.06
14-day deaths9 (33)40 (15)0.03
SAB-related deaths10 (37)47 (18)0.02
Deaths not related to SAB1 (4)20 (8)0.71
Recurrence0 (0)7 (3)0.39
Cure16 (59)200 (75)0.08
  • a Data are presented as the number (%) of patients unless indicated otherwise.

  • b Catheter was removed in 60 (92%) of 65 patients with catheter-related infection.

  • c A total of 218 patients, excluding 76 patients who died, were included in this analysis.